Business Context and Reporting Period
Company: Accuray Incorporated
Filing Type: Form 8-K (Current Report)
Date of Report: December 10, 2010
Event: Entry into a Material Definitive Agreement with CyberHeart, Inc.
Key Financial Metrics
This filing is a current report regarding a material agreement and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Agreement Details
On December 10, 2010, Accuray entered into two primary agreements with CyberHeart, Inc.:
- License Agreement: Accuray granted CyberHeart a non-exclusive license to certain intellectual property rights for the development and commercialization of radiation-delivery systems for non-tumor cardiovascular disease.
- Patent License: CyberHeart granted Accuray certain patent rights in the same field, exercisable only upon specific trigger events.
- Term: The License Agreement has an initial fifteen-year term commencing on the first date of human clinical treatment by CyberHeart using the licensed technology. It automatically renews for five-year terms unless notice of non-renewal is given 24 months prior to expiration.
- Financial Considerations: CyberHeart will pay specified royalties to Accuray on covered product sales. Accuray will pay specified royalties to CyberHeart on covered product sales. Specific royalty rates are not disclosed in this summary.
- Termination: CyberHeart may terminate for convenience with 30 days' notice. Either party may terminate for material breach.
- Superseding Prior Agreement: These agreements replace a prior License and Development Agreement dated April 27, 2007, effective upon the commencement of the new License Agreement.
Guidance, Outlook, and Risks
Management Commentary: Accuray intends to file the full text of the Agreements as exhibits to its Quarterly Report on Form 10-Q for the quarter ended December 31, 2010. The company intends to seek confidential treatment for certain terms and provisions.
Risks and Contingencies: The filing notes that the description of the agreements is a summary and is qualified in its entirety by reference to the complete text when filed. The effectiveness of the Patent License is contingent upon the occurrence of certain trigger events.
Key Facts for Investor Verification
- Verify the specific royalty rates and payment structures in the full text of the Agreements filed in the subsequent Form 10-Q.
- Confirm the definition of "trigger events" required for Accuray to exercise rights under the Patent License.
- Monitor the timeline for the first human clinical treatment by CyberHeart, as this date initiates the fifteen-year term of the License Agreement.
- Review the confidential treatment requests to understand which financial or technical terms are redacted from public view.